Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756693 | 0.89 | PTGS2 (0.47) | PTGS2CCNB2CDK1CCNB1CDK5 | |
| SCHEMBL13756834 | 0.88 | CDK2 (0.43) | PTGS2CCNB2CDK1CCNB1CDK5 | |
| SCHEMBL13756691 | 0.88 | AURKA (0.54) | JAK2JAK3PTK2FGFR4BRD4 | |
| SCHEMBL13756753 | 0.88 | FGFR4 (0.50) | PTGS2CDK5CDK5R1JAK2JAK3 | |
| SCHEMBL13756846 | 0.87 | CDK2 (0.44) | PTGS2CCNB2CDK1CCNB1CDK5 | |
| SCHEMBL13756755 | 0.85 | PTK2 (0.48) | CDK5CDK5R1CDK2PTK2FGFR4 | |
| SCHEMBL13756800 | 0.85 | CDK2 (0.46) | CCNB2CDK1CCNB1CDK5CDK5R1 | |
| SCHEMBL13756828 | 0.84 | TTK (0.53) | JAK2JAK3PTK2EGFRBRD4 | |
| SCHEMBL13756767 | 0.83 | CDK2 (0.46) | PTGS2JAK2JAK3CCNT1CCNE1 | |
| SCHEMBL13756752 | 0.82 | BRD4 (0.49) | PTGS2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | PTGS2 2188/4885CCNB2 1392/4885CDK1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.